Navigation Links
Birth Defects Link With ACE Inhibitor Use, FDA Reports

Taking ACE inhibitor, a common BP medication during first trimester of pregnancy have greater risk of developing birth defects in babies - The Food and Drug Administration reports from data collected by researchers at// Vanderbilt University Medical Center.

The study, led by William Cooper, M.D., M.P.H., associate professor of Pediatrics at the Monroe Carell Jr. Children's Hospital at Vanderbilt, found infants born to mothers who took angiotensin converting enzyme inhibitors (ACE inhibitors) during the first trimester of pregnancy had an increased risk of major birth defects, compared with infants whose mothers did not take these medications.

Out of 29,507 infants whose TennCare records were examined for the study, 209 were exposed to ACE inhibitors in the first trimester only. When those babies were compared to the rest of the population, including babies exposed to other types of antihypertensive medications, they had more than double the risk of major birth defects, especially of the heart and central nervous system.

Cooper is first author on the study, which includes co-authors from the Departments of Pediatrics, Preventive Medicine and Biostatistics.

‘We knew ACE inhibitors were a possible cause of adverse fetal outcomes when exposure occurred later in pregnancy, but it has not been well studied in the first trimester,’ Cooper said. ‘We were very surprised that even after controlling for other risk factors, the TennCare records we examined showed a clear increase in a broad range of birth defects following first-trimester-only exposures.’

This research is important because of an increase in the number of women of childbearing age who develop high blood pressure and are prescribed ACE inhibitors. These drugs already carry a warning that they may cause injury and even death to the developing fetus when used during the second and third trimesters of pregnancy. The warning states that a woman should discontinue
'"/>




Page: 1 2

Related medicine news :

1. Birth weight key factor in heart diseases
2. FDA Approves Birth Control Skin Patch
3. IVF technique May Increase The Risk Of Birth Defects
4. Smoking Linked To Low Infant Birth Weight
5. Unpredictable Premature Birth
6. New Birth Control Pills increase the stroke risk
7. Epilepsy Drugs Can Enhance Risk of Birth Defects
8. Sex timing has no impact on risk of Birth defects
9. Birth weight may be influenced by genes
10. Dental Procedure Reduces Preterm Births
11. Low Birth Weight infants could have Problems in the Future
Post Your Comments:
(Date:10/8/2008)... HIV-test-kit.com is a new site aimed a....V. from the comfort and privacy of their own home... issue. It is hoped that through home tests more p...he AIDS virus. , New York...eople are getting more used to getting instant res...
(Date:10/8/2008)... Drug Information Association (DIA) wil...-7; Ottawa, Ontario, Canada) to discuss a number o...aceutical industry, health academia, and the healt... PA (PRWEB) October 8, 2008 -- The http://www.diah... host the http://www.diahome.org/diahome/FlagshipM...
(Date:10/8/2008)... AccurateAnswers™ support program...es for http://www.appointment-plus.com [online s... Scottsdale, AZ (PRWEB) October 8, 2008 -- ... scheduling software, continues to expand its soft...n most "software as a service" providers...
(Date:10/8/2008)... Juva Skin & Laser Center is well e...kin treatments in New York City. The facility is l...e, one of the latest skin resurfacing treatments t...e laser equipment. , New ...urgery and laser treatment industry is in the mids...
Breaking Medicine News(10 mins):Health News:HIV Test Kit Markets a New Development in the War Against the AIDS Virus, an Easy Home HIV Testing Device 2Health News:DIA 6th Canadian Annual Meeting Benefit and Risk Management: An Evolution in Progress 2Health News:Appointment-Plus Continues Innovation With Technical Support Program 2Health News:Upscale New York City Skin Care Center Juva Offering FDA Approved Fraxel re:fine System 2
...n therapy with the new biologic drug adalimumab an...es more effective for people with long-standing rh...gement // with methotrexate alone. It has been fou...ents who fail to respond to standard treatment. A...
... Duke Univ. has shown that the surgical outcome of...n non-diabetics. The results were published Aug. 1...// In the largest analysis of its kind, Duke Univ... found that patients with diabetes who require sur...
...s had said that short-acting Beta-agonist (SABA) p...or asthma morbidity of steroid and non-steroid use...Illinois Medicaid, with a diagnosis of asthma from...esearchers from Chicago, IL, obtained the claims f...
...cer does not discriminate between rich and poor, i...ebrities have succumbed to it and some have fought...mous// actresses and personalities who have suffer...ton-John -Actress and SingerShirley Temple Black -...
Other Medicine News:Health News:Ankle Fracture Surgery – Diabetics fare worse than non-diabetics 2Health News:Ankle Fracture Surgery – Diabetics fare worse than non-diabetics 3
(Date:10/6/2008)... - Data Presented at ACG Annual Scient...ire/ -- Ironwood Pharmaceuticals,(formerly Microbi...r of,preclinical studies delineating the role that...leviating intestinal pain. These studies,demonstra...ical model of,intestinal hyperalgesia and desensit...
(Date:10/6/2008)... Experts Discuss Promising Research at The Amer... Annual Meeting, WASHINGTON, Oct. 6 /PRNewswir...n children and seniors was presented at The Americ...symposium, "Practical Applications of,Probiotics i...ields of,pediatrics, aging, and nutrition discusse...
(Date:10/6/2008)... PLYMOUTH MEETING, Pa., Oct. 6 /PRNewswire-Fi...oday reported data from its second Phase 1,clinica...d drug candidate,for the treatment of type 2 diabe...PTP1B, a validated molecular target that controls ...ys to normalize glucose and decrease,appetite. In ...
(Date:10/6/2008)... - Conference Call Scheduled for 9:0...tCall/ -- Dendreon Corporation (Nasdaq:,DNDN) anno...rim analysis of,the Phase 3, randomized, double-bl...Prostate AdenoCarcinoma Treatment, also known as D...y and efficacy of the,investigational active cellu...
Breaking Medicine Technology:Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 2'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 3'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 4Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 2Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 3Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 4Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 2Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 3Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 4Louisiana Tech researchers investigate tracking sensors to assist Air Force 324 1Louisiana Tech researchers investigate tracking sensors to assist Air Force 324 2Louisiana Tech researchers investigate tracking sensors to assist Air Force 324 3Small Incisions Make Heart Valve Surgery Safer 918 1Small Incisions Make Heart Valve Surgery Safer 918 2Small Incisions Make Heart Valve Surgery Safer 918 3 26 239 3BDrug free treatments offer hope for older people in pain 915 1Medifast Announces Winners of Mother Daughter Challenge 912 1Medifast Announces Winners of Mother Daughter Challenge 912 2Medifast Announces Winners of Mother Daughter Challenge 912 3
...lood Glucose,Control and Progressive Weight Loss -... Amylin,Pharmaceuticals, Inc. and Eli Lilly and Co...owed BYETTA(R) (exenatide) injection,sustained imp...ight,loss through three and a half years of therap...vements in cardiovascular risk,factors in people w...
...2007--Gilead,Sciences, Inc. (Nasdaq:GILD) today an... evaluating the company,s once-daily,anti-HIV drug...ovir,DF) 300 mg as a potential treatment for chron...ary efficacy endpoint. The data show,that Viread i...al,drug Hepsera(R) (adefovir dipivoxil) among pati...
Other Medicine Technology:Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 2Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 4Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 5Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 6Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6
...ydroepiandrosterone sulfate (DHEA-S) is the sulfat...and by enzymatic conversion of DHEA in adrenal and...d secreted by the adrenal cortex, and is a precurs...A possesses relatively weak androgenic activity, w...
EL-RF-IgM is high sensitivity quantitative rheumatoid factor IgM.
The Diamedix immunosimplicity® Is- Rheumatoid Factor Test Kit is an EIA procedure intended for the quantitation of IgM antibodies to IgG antigen. The results are reported in IU/mL, traceable to t
The SYNCHRON CX4 Delta Specialty / Drug Clinical System is a random access analyzer that can consolidate Drugs of Abuse, TDM's and other specialty testing, such as thyroid, HbA1c and lipids in one co
Medicine Products: